Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (90)	10/28/2002 3:17:49 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

FHRX This was the report that made the stock tank on Jul.2, 2002.<g> "First Horizon Pharmaceutical Corp. announced that it expects to report 2nd Q revenues between $25 and $26 M and earnings between break-even and $.02 (excluding a previously reported charge of $2.2 million, or $.04 per share), related to the write-off of the remaining fees associated with the acquisition of Sular". They also issued guidance of revenues between $60 and $65M and earnings between $.20 and $.22 for the six-month period ending December 31, 2002. Analysts on average were expecting EPS of $.08 on revenues of $28.8 M for the 2nd Q and EPS of $.39 on revenues of $72.15 M for the 6Ms ending Dec.2002. Bernard